Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a One-Two punch of heat and drainage tame inoperable bile duct cancer?

NCT ID NCT05563870

Disease control Sponsor: Clinical Hospital Colentina Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial is testing a personalized treatment for people with inoperable perihilar cholangiocarcinoma, a type of bile duct cancer. The approach combines radiofrequency ablation — using heat to destroy tumor tissue — with complete drainage of bile ducts, guided by both endoscopy and radiology. The goal is to see if this protocol is feasible, safe, and effective at controlling local disease and improving outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiofrequency ablation via endoscopy and radiology guidance
What this could lead to
If successful, this approach could offer a new way to control local tumor growth and improve survival in patients with inoperable bile duct cancer.
What could go wrong
This is a small, early-phase trial with only 26 participants. The procedure carries risks such as infection, bleeding, or pancreatitis, and it is unclear if it will improve overall survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

26 people

The number who actually took part.

Started

Aug 2022

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * perihilar cholangiocarcinoma * locally advanced disease (unresectable) * M1 (limted to 1 site) Exclusion Criteria: * refusal to sogn the ICF * poor performance status (ECOG \>2) * surgically altered anatomy (i.e Bilroth II or Roux-en-Y interventions) * significant comorbidities * ASA score \>3 * life expectancy \<3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Perihilar cholangiocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hilar cholangiocarcinoma perihilar intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Perihilar cholangiocarcinoma

Contacts and locations

Locations

  • Gastroenterology Department, Colentina Hospital

    Bucharest, 020125, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.